tegafur has been researched along with Nasopharyngeal Carcinoma in 4 studies
Nasopharyngeal Carcinoma: A carcinoma that originates in the EPITHELIUM of the NASOPHARYNX and includes four subtypes: keratinizing squamous cell, non-keratinizing, basaloid squamous cell, and PAPILLARY ADENOCARCINOMA. It is most prevalent in Southeast Asian populations and is associated with EPSTEIN-BARR VIRUS INFECTIONS. Somatic mutations associated with this cancer have been identified in NPCR, BAP1, UBAP1, ERBB2, ERBB3, MLL2, PIK3CA, KRAS, NRAS, and ARID1A genes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to analyze the safety and feasibility of low-dose apatinib combined with S-1 as a second-line therapy or beyond in Chinese patients with pulmonary and/or hepatic metastases of nasopharyngeal carcinoma (NPC)." | 7.96 | Safety and Feasibility of Low-Dose Apatinib Combined with S-1 as the Second-Line Therapy or Beyond in Chinese Patients with Pulmonary and Hepatic Metastasis of Nasopharyngeal Carcinoma. ( Chen, J; Huang, X; Lin, J; Wu, G; Zhang, S; Zhou, L, 2020) |
| "The study was aimed to evaluate the impact of accumulated oral tegafur-uracil (UFUR) as maintenance chemotherapy on overall survival (OS) and disease-free survival (DFS) rates after concurrent chemoradiotherapy (CCRT) for complete remission (CR) in non-distant metastatic TNM stage IV nasopharyngeal carcinoma (NPC)." | 7.91 | Evaluation of oral tegafur-uracil as metronomic therapy following concurrent chemoradiotherapy in patients with non-distant metastatic TNM stage IV nasopharyngeal carcinoma. ( Chao, TY; Chen, JH; Ho, CL; Huang, WY; Lee, JC, 2019) |
| "The purpose of this study was to analyze the safety and feasibility of low-dose apatinib combined with S-1 as a second-line therapy or beyond in Chinese patients with pulmonary and/or hepatic metastases of nasopharyngeal carcinoma (NPC)." | 3.96 | Safety and Feasibility of Low-Dose Apatinib Combined with S-1 as the Second-Line Therapy or Beyond in Chinese Patients with Pulmonary and Hepatic Metastasis of Nasopharyngeal Carcinoma. ( Chen, J; Huang, X; Lin, J; Wu, G; Zhang, S; Zhou, L, 2020) |
| "The study was aimed to evaluate the impact of accumulated oral tegafur-uracil (UFUR) as maintenance chemotherapy on overall survival (OS) and disease-free survival (DFS) rates after concurrent chemoradiotherapy (CCRT) for complete remission (CR) in non-distant metastatic TNM stage IV nasopharyngeal carcinoma (NPC)." | 3.91 | Evaluation of oral tegafur-uracil as metronomic therapy following concurrent chemoradiotherapy in patients with non-distant metastatic TNM stage IV nasopharyngeal carcinoma. ( Chao, TY; Chen, JH; Ho, CL; Huang, WY; Lee, JC, 2019) |
| " Most adverse events were mild." | 1.40 | Safety and efficacy of S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy: multi-institutional retrospective analysis. ( Chen, ZB; Cheng, H; Lin, Z; Liu, YM; Ou, XQ; Peng, PJ; Tang, YN; Wang, SY; Wu, X; Zeng, LJ; Zhang, HY, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, JH | 1 |
| Huang, WY | 1 |
| Ho, CL | 1 |
| Chao, TY | 1 |
| Lee, JC | 1 |
| Zong, J | 1 |
| Xu, H | 1 |
| Chen, B | 1 |
| Guo, Q | 1 |
| Xu, Y | 1 |
| Chen, C | 1 |
| Weng, Y | 1 |
| Zheng, W | 1 |
| Pan, J | 1 |
| Lin, S | 1 |
| Zhou, L | 1 |
| Lin, J | 1 |
| Wu, G | 1 |
| Chen, J | 1 |
| Huang, X | 1 |
| Zhang, S | 1 |
| Peng, PJ | 1 |
| Cheng, H | 1 |
| Ou, XQ | 1 |
| Zeng, LJ | 1 |
| Wu, X | 1 |
| Liu, YM | 1 |
| Lin, Z | 1 |
| Tang, YN | 1 |
| Wang, SY | 1 |
| Zhang, HY | 1 |
| Chen, ZB | 1 |
4 other studies available for tegafur and Nasopharyngeal Carcinoma
| Article | Year |
|---|---|
Evaluation of oral tegafur-uracil as metronomic therapy following concurrent chemoradiotherapy in patients with non-distant metastatic TNM stage IV nasopharyngeal carcinoma.
Topics: Administration, Metronomic; Administration, Oral; Adult; Antimetabolites, Antineoplastic; Chemoradio | 2019 |
Maintenance chemotherapy using S-1 following definitive chemoradiotherapy in patients with N3 nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Chemoradiotherapy; Drug Combinations; Female; Humans; Maintenance Chemother | 2019 |
Safety and Feasibility of Low-Dose Apatinib Combined with S-1 as the Second-Line Therapy or Beyond in Chinese Patients with Pulmonary and Hepatic Metastasis of Nasopharyngeal Carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Car | 2020 |
Safety and efficacy of S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy: multi-institutional retrospective analysis.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma; Disease Progression; Drug Combinations; Fem | 2014 |